Since joining the firm, Bang-Andreasen has focused on scaling portfolio companies and deepening the firm's reach into innovation ecosystems. He currently holds board positions at PL BioScience, Abbelight, and PathPresenter. Founding General Partner Daniella Kranjac noted that his leadership proved vital during the launch of Fund II and continues to drive the firm's strategic initiatives.
Ole Henrik Bang-Andreasen Named Partner at Growth Equity Firm AVANT BIO
Ole Henrik Bang-Andreasen has been elevated to Partner at AVANT BIO, a move underscoring his influence on the firm’s investment strategy and its expanding footprint within the European life sciences market. The appointment follows his instrumental work in identifying growth-stage opportunities across the therapeutic enabling technology sector.
His career spans a decade of experience in public and private life science markets, including roles at Tower House Partners and ABG Sundal Collier. His background also includes competitive athletics as a professional cyclist and a national team rower for Norway. Bang-Andreasen aims to solidify the firm’s status as a primary financier for life science industrials globally, continuing to bridge the gap between emerging technologies and market delivery.
Comments (0)
No comments yet. Be the first!